Scoliosis : An update on treatments for children and adolescents Puzzler : Acute shock during Lent Dermcase : More than "Ugg-ly" feet Streamlining your office with technology
FDA issues second CRL for dasiglucagon to treat hypoglycemia in congenital hyperinsulinism
Published: October 8th 2024 | Updated: October 8th 2024This decision marks the second time the FDA has issued a complete response letter (CRL) for dasiglucagon to treat hypoglycemia in patients 7 days and up with congenital hyperinsulinism.